康泰佐利德在复杂腹腔内感染的治疗效果
Yongsheng Zhao1, Xianlei Xin1, Bin Wang1
1Faculty of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China.
Infection and drug resistance
|August 12, 2024
概括
康泰佐利德在治疗由格拉姆阳性细菌引起的复杂腹内感染方面表现有前途. 这种抗生素有助于降低患者的发烧和炎症,表明其潜在的临床效用.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 复杂的腹腔内感染 (cIAI) 带来了重大治疗挑战,通常涉及多抗药性格拉姆阳性细菌.
- 之前治疗格拉姆阳性感染的疗法包括linezolid,teicoplanin和vancomycin,但耐药性和治疗失败需要新药.
研究的目的:
- 评估康特佐利德在患有复杂腹部内感染的患者的疗效和安全性.
- 评估康特佐利德对发烧和炎症标志物等临床参数的影响.
主要方法:
- 一项回顾性研究,涉及12名在2022年1月至2023年4月期间接受康特佐利德治疗的cIAI患者.
- 收集的数据包括患者人口统计学,感染类型,致病原体 (主要是格拉姆阳性细菌),先前使用抗生素,治疗持续时间和临床结果.
主要成果:
- 康泰索利德用于患有严重急性胰腺炎,术后感染和创伤相关的CIAI的患者.
- 11名患者患有格拉姆阳性细菌感染,包括Enterococcus faecium和Staphylococcus物种,通常是在先前使用其他抗生素治疗后.
- 康特佐利德的治疗导致体温显著下降,并降低了IN-6 (IL-6) 水平,并增加了血小板数量.
结论:
- 康泰索利德显示出作为一种有效的治疗选择,用于由格拉姆阳性细菌引起的复杂腹内感染的潜力.
- 观察到的发烧和炎症标志物的减少表明,除了抗微生物活性外,还有有益的免疫调节作用.
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:21Drugs for Treatment of Constipation-Predominant IBS
149
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
149
01:29Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
01:17Chronic Bowel Disorders: Introduction
436
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
436
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124